Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769608 · ClinicalTrials.gov registry record · Phase 2
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Phase 2 study of Hypertension, sponsored by Mineralys Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT05769608 is a Phase 2 study of Hypertension that has completed, run by Mineralys Therapeutics. The registered enrollment target is 285 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT05769608, a Phase 2 study of Hypertension, has completed, sponsored by Mineralys Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG lorundrostat Dose 1
- DRUG lorundrostat Dose 2
Study Locations (20)
California
- The Medical Research Group Inc. - Fresno
- Marvel Clinical Research - Huntington Beach
- University of California San Diego (UCSD) - Altman Clinical and Translational Research Institute (ACTRI) - La Jolla
- Clinical Trials Research - Lincoln
- Cedars-Sinai Medical Center - Los Angeles
- Catalina Research Institute - Montclair
- Northridge Clinical Trials - Northridge
- University of California Irvine Medical Center - Orange
- Triwest Research Associates - San Diego
- San Jose Clinical Trials - San Jose
- Blue Coast Research Center - Vista
- Accelerated Enrollment Solutions (AES)- Vista - Vista
Arizona
- Chandler Clinical Trials - Chandler
- Brown Road Family Medicine - Mesa
- Scottsdale Clinical Trials (Elite Clinical Network) - Scottsdale
- Fiel Family & Sports Medicine - Tempe
- Noble Clinical Research - Tucson
- Del Sol Research Management, LLC - Tucson
Alabama
- Cardiology, P.C. - Birmingham - Birmingham
- University of Alabama at Birmingham (UAB) - Vascular Biology and Hypertension Program - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769608
The ClinicalTrials.gov registry entry for NCT05769608 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The listed sponsor is Mineralys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05769608 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05769608 about?
NCT05769608 is a clinical study titled "A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen". A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.
What is the current status of trial NCT05769608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2023-03-13. Estimated completion is 2025-01-15.
What conditions does trial NCT05769608 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT05769608?
The interventions under investigation include: Placebo (DRUG), lorundrostat Dose 1 (DRUG), lorundrostat Dose 2 (DRUG).
Who is sponsoring clinical trial NCT05769608?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769608 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.